Cargando…
Enhanced production of recombinant serratiopeptidase in Escherichia coli and its characterization as a potential biosimilar to native biotherapeutic counterpart
BACKGROUND: Serratia marcescens, a Gram-negative nosocomial pathogen secretes a 50 kDa multi-domain zinc metalloprotease called serratiopeptidase. Broad substrate specificity of serratiopeptidase makes it suitable for detergent and food processing industries The protein shows potent anti-inflammator...
Autores principales: | Srivastava, Vishal, Mishra, Shivam, Chaudhuri, Tapan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918600/ https://www.ncbi.nlm.nih.gov/pubmed/31847856 http://dx.doi.org/10.1186/s12934-019-1267-x |
Ejemplares similares
-
The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020) -
Asymptomatic Bacteriuria Escherichia coli Are Live Biotherapeutics for UTI
por: Rudick, Charles N., et al.
Publicado: (2014) -
Production and Expression Optimization of Heterologous Serratiopeptidase
por: ROUHANI, Maryam, et al.
Publicado: (2020) -
Serratiopeptidase: Insights into the therapeutic applications
por: Jadhav, Swati B., et al.
Publicado: (2020) -
The role of serratiopeptidase in the resolution of inflammation
por: Tiwari, Manju
Publicado: (2017)